Acelyrin, Inc. (SLRN)

4.2500 +0.0700 (+1.67%) At close: 04:00PM EDT

Acelyrin, Inc.

4149 Liberty Canyon Road
Agoura Hills, CA 91301
United States
805-730-0360
https://www.acelyrin.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 135

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Shao-Lee Lin M.D., Ph.D.	Co-Founder, CEO & Director	891.59k	N/A	1967
Ms. Melanie Gloria B.S.N.	Chief Operating Officer	667.52k	N/A	1978
Mr. Ron Oyston	Chief People Officer	551.96k	N/A	1970
Mr. Gilbert M. Labrucherie J.D.	Chief Financial Officer	N/A	N/A	1972
Ms. Mina Kim	Chief Legal & Administrative Officer and Corporate Secretary	N/A	N/A	1974
Mr. Tyler Marciniak	Head of Investor Relations & Communications	N/A	N/A	N/A
Dr. Paul M. Peloso M.D., M.Sc.	Chief Medical Officer	N/A	N/A	1958
Ms. Suzy Buckhalter CPA	Senior Director of Finance & Accounting	N/A	N/A	N/A
Mr. Kenneth A. Lock	Chief Commercial Officer	N/A	N/A	1974
Dr. Shephard Mpofu M.D.	Senior Vice President of Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

Corporate governance

Acelyrin, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.